PROTALIX BIOTHERAPEUTICS INC
PLXNYSE AMERICANTrading Snapshot
- Day Range
- $2.66 – $2.71
- 52-Week Range
- $1.60 – $3.19
- Volume
- $3.34B
- Avg Volume
- $2.44B
- Shares Outstanding
- 80.6M
- Next Earnings
- Oct 29, 2026
Fundamentals Snapshot
- Annual Revenue
- $53M
- Last Q Revenue
- $20M
- P/E Ratio
- 11.2
- P/S Ratio
- 2.7x
- EPS (TTM)
- $0.24
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −3.1%
Why Investors Own PLX
- ✓High-growth profile — revenue up +12.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 53% gross margin and 29% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
PROTALIX BIOTHERAPEUTICS INC
PLX
StockOtter · stockotter.spaceAbout PROTALIX BIOTHERAPEUTICS INC
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Protalix BioTherapeutics, Inc. (PLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Protalix BioTherapeutics, Inc. (PLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences
CARMIEL, Israel, Sept. 8, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative thera
Protalix BioTherapeutics, Inc. (PLX) Q2 2026 Earnings Call Transcript
Protalix BioTherapeutics, Inc. (PLX) Q2 2026 Earnings Call Transcript
Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results
Company to host conference call and webcast today at 8:00 a.m. EDT Revenues from selling goods increased to $19.8 million in the second quarter of 2026, up $4.4 million from the second quarter of 2025, driven primarily b
Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026
Company to host conference call and webcast at 8:00 a.m. EDT CARMIEL, Israel, Aug. 5, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, develo